XXXXXXXX KOMISE X XXXXXXXXX XXXXXXXXX (XX) č. 1062/2014
xx xxx 4. xxxxx 2014,
xxxxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx, xxxxx xxxx xxxxxxx x xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 528/2012
(Xxxx x xxxxxxxx pro XXX)
XXXXXXXX XXXXXX,
x xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,
x xxxxxxx na xxxxxxxx Evropského parlamentu x Xxxx (XX) x. 528/2012 xx xxx 22. května 2012 x dodávání xxxxxxxxxx přípravků xx xxx a xxxxxx xxxxxxxxx (1), x xxxxxxx xx xx. 89 xxxx. 1 první xxxxxxxxxxx uvedeného nařízení,
xxxxxxxx x těmto xxxxxxx:
|
(1) |
Nařízení Xxxxxx (XX) č. 1451/2007 (2) xxxxxxx prováděcí pravidla xxx program xxxxxxxx xxxxxxxxxxx biocidních xxxxxxxx xxxxx (dále xxx „xxxxxxx přezkumu“), xxxxx xxx zahájen x xxxxxxx x xx. 16 xxxx. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Rady 98/8/XX (3). Xxxxxxx xxxx xxxxxxxx xxxx xxxxxxx x xxxxxxxxx nařízením (EU) x. 528/2012, měla xx xxx xxxxxxxxx xxxxxxxx xxx pokračování xxxxxxxx xxxxxxxx přizpůsobena xxxxxxxxxxx xxxxxxxxx nařízení. |
|
(2) |
Xx důležité xxxxx xxxxxxxxx účinné xxxxx x xxxx xxxxxxxxx, xxxxx xxxxx xxx xxxxxxxx xx xxx x xxxxxxxxx podle přechodných xxxxxxxxxx xxxxxx 89 xxxxxxxx (XX) x. 528/2012 s výhradou xxxxxxxxxxxxxx xxxxxxxx. Mělo xx xxxx xxx x v případě xxxxxxxxx xxxxxx xxxxx x typu přípravku, xxxxx xxxx xxxxxxxxx x xxxxxxxx xxxxxxxx. |
|
(3) |
Xxxxx xxxxxxxxx xxxxxxxx odchylky xxx xxxxxxxxx a krmiva xxxxx článku 6 xxxxxxxx (ES) x. 1451/2007, xxx xxxxxxxxxx xx xx něj xxxxxxx xxx xxxxxxxxx x xxxxxx xxxxxxx x xx. 2 xxxx. 5 xxxx. x) xxxxxxxx (XX) x. 528/2012, měly xx xxx účinné látky, xxxxx xxxxxxxx, hodnoceny x xxxxxxxx xxxxxxxx pro xxxxxxxxx xxx přípravku. X xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xx mělo xxx xxxxxx dodávání xx xxx x xxxxxxxxx umožněno až xx xxxxxxxx xxxxxxxxx hodnocení. Xxxxxx xxxxxxxxxxx xxxxxxxxxx xx xxx xxxxxxx, xxxxx xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxx. Totéž xx xxxx xxxxxx x xxxxxxxxx, xxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx vyplynulo x xxxx definice xxxx xxxxxxxxx v nařízení (XX) x. 528/2012 xxxxxx xxxxxxxx xxxxxxx xx xxxxxxxx 98/8/ES xxxx xx xxxxx xxxxxxxxxx xxxxxxxxxxx Xxxxxx xxxxxxxx x xxxxxxx x xx. 3 odst. 3 xxxxxxxx (EU) č. 528/2012, xxxxxxxxxxx (například rozhodnutím xx věci X-420/10 (4)) xxxx závaznými pokyny Xxxxxx xx příslušných xxxxxx xxxxxxxxx xxxxx, xxxxx se xxxxxxxx xxxxxxx. |
|
(4) |
Xxxxx xxxxxxxx přípravek xxxxxxxx účinnou xxxxx, xxxxx již xxxx xxxxxxxx xx programu xxxxxxxx, x této xxxxx sestává nebo xx x xx xxxxxx, xxxxx xxxxxxxx xx xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx v členském xxxxx nezbytné, xxxx xx být v tomto xxxxxxxx státě použití x xxxxxxxx xx xxx xxxxxxxx na jeho xxxxxxxxxxxx, xx xxxxxxxx xxxxxxxx x xx omezenou xxxx. |
|
(5) |
X zájmu xxxxxxxxxxx x xxxxxxxxxxxx xx měl xxx postup xxxxxxxxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxx ve xxxxx xxxxxxxxxx xxxxxxx xxxxxxx x postupem stanoveným xxx žádosti xxxxxxxxxx xxxxx xxxxxx 7 xxxxxxxx (XX) x. 528/2012 nebo xxxxx prováděcího xxxxxxxx Xxxxxx (XX) x. 88/2014 (5). |
|
(6) |
Pro xxxxx, xxxxx splňují xxxxxxxx xxxxxxxxx xxxx xxxxxxxx xxx xxxxxxx, xx měl hodnotící xxxxxxxxx xxxxx předložit xxxxxxxx návrh xxxxxxxxxxxxx xxxxxxxxxxx a označení látky xxxxx čl. 37 xxxx. 1 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) č. 1272/2008 (6), xxxxx jde x xxxxxxxxx vlastnosti xxxxxxxxxx xxxxx, x xxxxxxx by xxxx být xxxxxxxxx xxxxx členského xxxxx xxxxxxxxx návrh xxxxxxxx xx xxxxxx nebo xxxxx xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx příslušný xxxxx xx xxx také xxxxxxxxxxx xxxxxxxx x xxxxxxx xxxxx, xxxxx xx xxxxxxxxx xxxxxxxx xxx látky xxxxxxxxxxxx, xxxxxxxxxxxxxxx xx xxxxxxx, xxxx xxxxx, xxxxx xx xxxxx xxx xxxxxxxxxx xx xxxxx x xxxxxxxxxxx xxxxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx. |
|
(7) |
Xxx bylo xxxxxxxxx, xx program přezkumu xxxx xxxxxxxx xx xxxxxxxx xxxx xxxxxxxxx x xx. 89 odst. 1 xxxxxxxx (XX) č. 528/2012, mělo xx xx xxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx, u xxxxx xxxx xxxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx x xxxxxxxx (XX) č. 1451/2007 xxxx v tomto nařízení. Xxxxx xxxx by xx xxxx xxxxxxxx xxxxxx xxxxx pro xxxxxxxxx xxxxxxxxx, xxxxxxx xx se xxxx xxxx x xxxxx xxxxxxx, že xxxxxxx xx mohly být xxxxxxxxx méně než xxx xxxx xxxxxxxxx xxxxxx lhůt. |
|
(8) |
Xxxxxxx xxxxxxxx xx xxxxxxx I xxxxxxxxx 7 nařízení (XX) x. 528/2012 dosud xxxxxx xxxxxxxxx xxxxx xxxxxxxxx xx xxxxx. Xx proto xxxxxx x xxxx xxxx xxxxxx xxxxxxx x xxxxxxxx xx uvedené přílohy xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6. |
|
(9) |
Bez xxxxxx na čl. 90 odst. 2 xxxxxxxx (XX) č. 528/2012 xxxxxxx x xxxxxx 91 xxxxxxxxx xxxxxxxx, xx xxxxxxxx xxxxxxx x xxxxxx 10 xxxxxxxxx nařízení xx xxxx být xxxxxxxxxx xxx následné xxxxxxxxxx xxxxxxxxxx přípravků ve všech xxxxxxxxx. Xx xxxxx xxxxxx určit xxxxx xxxxxxxxx xxxx kritéria xx xxxxx xxxxxxxxxxx účinných xxxxx. |
|
(10) |
Xxxxxxxxxxx xxxxxxxx programu xxxxxxxx by měl xxx možnost xx xx xxxxxxxx xxxxxx xxxxxxxx ke stávajícímu xxxxxxxxxxx xxxx jej xxxxxxxx xx xxxxxxxxxxx, xx xxxxx tomu xxxxxxx ke xxxxxxxx xxxxxxxxx z důvodu xxxxxxxxx xxxxxxxx x údajům, xxxxxxx xxxxx by xxxxxxxxxxx účastník musel xxxxxxxxx xxxxx znovu. |
|
(11) |
Xxxxxxx xx xxxxx x xxxxxxxx xxxxxxxx dobrovolná, xxxx xx být xxxxxxxxxx xxxxxxxx od xx xxxxxxxxx. Pokud x xxxx dojde, měli xx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx xxxxxxx, nebylo-li xxxx xxxxxxxx xxxxxxx xxx xxxxxx, neboť tím xxxxxxx xx xxxxxxxx xxxxxxxx xxxxxxxx, x xxxxxxxx-xx xxxxxxxx xxx xxxxxxxx na svém xxxxxxxxxx. |
|
(12) |
Xxxxx xx xxx xxxxxxxxx xxxxxx xxxxx xxxxx, xx xxxxxxxx oficiálně xxxxxxxx do programu přezkumu xxxxxx neodpovídá identitě xxxxxxxx xxxxxxxxx xxxxx, x x xxxxxxxxx xxxxx xxxxxxx xxxxxx xxxxxxx xxxxxxxx xxxxxxxxx zařazené xxxxx, xxxx xx xxx xxxxx xxxx xxxxx x xxxxxxx hodnocení xxxxx definovat x xxxxxxx xxxxx xxxxxx, aby xxxxxxxx podporu této xxxxxxxxx xxxxxxxx xxxxx. |
|
(13) |
Xxxxxxx xxxxx zařazené xx xxxxxxxx xxxxxxxx nejsou x době přijetí xxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xxxxxxxxxx. Xxxxx xx xxxx xxxxxxxx xxxxxxxxxxxxx, xxxxxx xxxxx xx. 4 xxxx. 4 xxxxxxxx (XX) x. 528/2012 tyto xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxx xxxx xxxxxxxx xxxxxxxxx. X xxxxxxxxx xxxxx x xxxxxxxxxxxxx xx měly xxx xxxxx xxxxxxx xxxxxxx xxxxx, xxxxxxx xxxxx xx xxxx xxxxx a nanomateriály musely xxx x xxxxxxxx xxxxxxxx xxxxxxxxx. |
|
(14) |
Aby xxxx xxxxxxxxx, že xxxxx xxxxx xxxxxxxxx x xxxxxxxx xxxxxxxxxxx xxx xx xxx nebude xxxxxxxx, aniž xx xxxxxxxx xxxx xxxxxxxxxxx, xxxx by xxxxxxxx xxxxx, xxxxx ještě xxxxxx xxxxxxxxx, x xxxxxxxx xxxx xxxx xxxxxxxx xxxxxxxx oznamování xxxxxxxxxx údajů x xx, |
XXXXXXX TOTO XXXXXXXX:
XXXXXXXX 1
XXXXXXX X XXXXXXXX
Xxxxxx 1
Xxxxxxx
Xxxx xxxxxxxx xxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxx programu xxxxxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx x&xxxx;xxxxxx&xxxx;89 nařízení (XX) x.&xxxx;528/2012.
Xxxxxx 2
Definice
Xxx účely xxxxxx xxxxxxxx xx xxxxxxx xxxx xxxxxxxx:
|
a) |
„xxxxxxxxxxx x xxxxxxxxxxx“ xx xxxxxx xxxxxxxxxx neschválit xxxxxxxxx látky x xxxx xxxxxxxxx xxxxx čl. 9 xxxx. 1 písm. b) xxxxxxxx (XX) x. 528/2012 xxxx xx. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx, xxxx xxxxxxxxx xxxxxxxxx xx xxxxxxx X xxxx IA xxxxxxxx 98/8/ES; |
|
x) |
„xxxxxxxxx látky x xxxx xxxxxxxxx zařazenou xx xxxxxxxx xxxxxxxx“ xx xxxxxx kombinace xxxxx x xxxx xxxxxxxxx xxxxxxx x xxxxxxx XX, xxxxx xxxxxxx xxxx podmínky:
|
|
x) |
„xxxxxxxxxx“ xx xxxxxx xxxxx, xxxxx xxxxxxxxxx žádost x xxxxxxxxx látky a typu xxxxxxxxx zařazené xx xxxxxxxx xxxxxxxx nebo xxxxxxxxxx xxxxxxxx, xxxxx odpovídá xxxxxxxxxx xxxxx xx. 17 xxxx. 5 xxxxxx xxxxxxxx, xxxx xxxxxx xxxxxx xxxx xxxx xxxxxx xxxx xxxxxxxx předloženo; |
|
d) |
„xxxxxxxxxx xxxxxxxxxx xxxxxxx“ se xxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxxx x příloze II xxxxxx nařízení, určený x xxxxxxx x xxxxxxx 81 xxxxxxxx (XX) č. 528/2012. |
XXXXXXXX 2
XXXXXX XXXXXXXXX XXXXXXXXXXX
Xxxxxx 3
Xxxxxx x xxxxxxxxx nebo xxxxxxxx xx přílohy I xxxxxxxx (XX) x. 528/2012
1.&xxxx;&xxxx;&xxxx;Xxxxxx x&xxxx;xxxxxxxxx xx xxxxxxxx xx&xxxx;xxxxxxx X&xxxx;xxxxxxxx (XX) x.&xxxx;528/2012 může xxxxx xxxxx xxxxxxxx, x jehož xxxxxxxx xxxxx xxxxxxxx x xxxxxx, že odpovídá xxxxxxxxxx xxxxx xx.&xxxx;17 xxxx.&xxxx;5 xxxxxx xxxxxxxx.
Xxxxx xx xxxxxx týká xxxxxxxx xx&xxxx;xxxxxxx X&xxxx;xxxxxxxx (XX) č. 528/2012, xxxx xx xxxxx xxxxx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx xxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxxxxx x&xxxx;xxxxxxxx 1 se podávají xxxxxxxx do dvou xxx xx xxxxxxxxxx x&xxxx;xxxxxxx x xxxxxxxxx podle xx.&xxxx;17 odst. 5.
Xxxxxx 4
Xxxxxxx xxxxxxx
1. Xxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx Xxxxxx (XX) č. 564/2013 (7) x xxxxxxx xxxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx ve lhůtě 30 xxx. X xxxx xxxxxxxxxxx informuje xxxxxxxxx i xxxxxxxxx xxxxxxxxx xxxxx.
2. Po obdržení xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx (EU) x. 564/2013 xxxxxx xxxxxxxx xxxxxx x xxxxxxxxx x xxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx orgán, xxxxxxx xxxxx xxxxx xxxxxxx žádosti a její xxxxxxxxx xxxxxxxxxxxxx kód.
3. Proti xxxxxxxxxxx agentury xxxxx xxxxxxxx 1 xxxxxx xxxxxx xxx podat xxxxxxx xxxxxxxxxx x xxxxxxx x xxxxxxx 77 xxxxxxxx (EU) x. 528/2012.
4. Xxxxxxxxx příslušný xxxxx informuje xxxxxxxxx x xxxxxxxx xxxxxxxx xxxxx čl. 80 xxxx. 2 xxxxxxxx (XX) č. 528/2012 xx 30 dnů xxxx, xx xxxxxxxx xxxxxxx žádost, x xxxxxxx xxxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx lhůtě 30 xxx. X xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx.
Xxxxxx 5
Potvrzení xxxxxxx x schválení xxxx xxxxxxxx xx xxxxxxxxx 6 xxxxxxx X xxxxxxxx (XX) č. 528/2012
1. Xxxxx agentura xxxxxx xxxxx xx. 4 xxxx. 2 xxxxxx x xxxxxxxxx xxxx zařazení xx xxxxxxxxx 6 xxxxxxx X xxxxxxxx (EU) x. 528/2012, xxxxx xxxxxxxx údaje xxxxxxxxxx x xxxxxxx x xx. 6 xxxx. 1 a 2 xxxxxxxxx nařízení, a byl xxxxxxxx poplatek podle xx. 4 odst. 4, xxxxxxxxx xxxxxxxxx xxxxx žádost xxxxxxx xx 30 xxx xx zaplacení xxxxxxxx.
2. Pokud xxxxxxxxx příslušný orgán xxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx nařízení (XX) x. 1451/2007, xxxxx ta xxxxx nebyla xxxxxx xxxx xxxxx xxxxx xxxxxx 13 uvedeného xxxxxxxx, xxxxxxx hodnotící xxxxxxxxx xxxxx žádost xxxxxxxxxx xx 3. ledna 2015.
3. X případech xxxxxxxxx x xxxxxxxxxx 1 x 2 xxxxxxxxx xxxxxxxxx xxxxx neprovádí xxxxxxxxx xxxxxxx xxx xxxxxxxxxxxx předložených údajů xxxx xxxxxxxxxx.
4. Pokud xxxxxxxxx xxxxxxxxx xxxxx xxxxxx, xx žádost xx xxxxxxx, xxxxx účastníkovi, xxxx doplňující informace xxxx k potvrzení xxxxxxx xxxxx, x x xxxxxxxxxx xxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxx. Tato lhůta xxxxx xxxxxxxxxx 90 xxx.
Rozhodne-li xxxxxxxxx xxxxxxxxx orgán, xx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx postačují ke xxxxxxx xxxxxxxxx uvedených x xxxxxxxx 2, xxxxxxx xxxxxx xx 30 xxx od xxxxxxxx xxxxxxxxxxxx xxxxxxxxx.
Xxxxxxxx xxxxxxxx xxxxxxxxxx informace xx xxxxxxxxx lhůtě xxxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxx xxxxxx xxxxxxx x xxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxx. X xxxxxx xxxxxxxxx se xxxxx poplatky xxxxxxxxx x xxxxxxx s čl. 80 odst. 1 x 2 nařízení (XX) x. 528/2012.
Xxx xxxxxxxxx žádosti xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxxxxxx x xxxxx příslušné xxxxxx x xxxxx datum xxxxxx xxxxxxxxx.
Xxxxxx 6
Hodnocení žádostí
1. Xxxxx xxxxxx xx xxxxxxx, xxxxx xxxxx některá x xxxxxx podmínek:
|
x) |
xx-xx žádost xxxxxxxxx xxxxx článku 5; |
|
x) |
xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxx dokumentaci xxxx xxxxxx xxxxx xxxxxx 13 nařízení (XX) x. 1451/2007, xxx xxxxx xxxxxxxxxxx Komisi xxxxxx xxxxxxxxxxx xxxxxx podle xx. 14 odst. 4 xxxxxxxxx xxxxxxxx; |
|
x) |
xxxxx xxxxxxxx přijala xxxxxx x zařazení xx xxxxxxxxx 1, 2, 3, 4 nebo 5 přílohy I nařízení (XX) x. 528/2012 xxxxx xx. 4 odst. 2 x xxx xxxxxxxx poplatek xxxxx xx. 4 odst. 4. |
2. Xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx xxxxxx xxxxx článků 4 x 5 xxxxxxxx (XX) x. 528/2012 x xxxxxxxx xxx xxxxxxx xxxxxx xx xxxxxx xxxxxxxxx xx xxxxx předložené x xxxxxxx x xx. 6 xxxx. 3 xxxxxxxxx nařízení x zašle xxxxxxxxx xxxxxx x xxxxxx xxxxx xxxxxxxxx agentuře.
3. Xxxxx xxxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx xxxxxxxxx xxxxxxx účastníků, xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx pouze xxxxx xxxxxxxxx xxxxxx. Xxxxxxxxx xxxxxx a závěry xxxxx x xxxxx x xxxxxx xxxx, xxxxx toho, xx xxxxxxx xxxxxxx:
|
x) |
365 xxx xx xxxxxxxxx xxxxxxxxx xxxxxxxx x xxxx. 1 xxxx. x), xxxxxx úplnosti xxxxxxxx x xxxx. 1 xxxx. x) xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx x xxxx. 1 xxxx. x) x xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx; |
|
x) |
ve xxxxx xxxxxxxxx x xxxxxxx XXX. |
4. Xxxx xxx, xxx xxxxxxxxx xxxxxxxxx orgán xxxxxxxx xxx xxxxxx xxxxxxxx, xxxxxx účastníkovi xxxxx do 30 xxx k hodnotící xxxxxx a x xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx xxxxx tyto xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx zohlední x závěrečné fázi xxxxx xxxxxxxxx.
5. Xxxxx se xxxxx, že jsou x hodnocení xxxxx xxxxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx, xxx xxxx xxxxxxxxx ve stanovené xxxxx xxxxxxxxx, x xxxxxxxxx x tom xxxxxxxx.
Xxxxx 365 dnů xxxxxxx x xxxxxxxx 3 se xxxxxxx xx xxxx xxx xxx vznesení xxxxxxxxx xx xxx xxxxxxxx xxxxxxxxx. Xxxxx xx xxxx odůvodněno xxxxxxx xxxxxxxxxxxx xxxxx nebo xxxxxxxxxxx xxxxxxxxxx, přerušení xxxxxxxxxx xxxxxxxxxxx xxxxx:
|
x) |
365 xxx x xxxxxxx, xx xx doplňující xxxxxxxxx xxxxxx xxxxxx, které xxxxxx xxxxxx v xxxxx xxxxxxxx 98/8/ES xxxx v rámci postupů xxxxxxxxxxx pro uplatňování xxxxxxx xxxxxxxx; |
|
b) |
180 dní xx xxxxx xxxxxxxxx xxxxxxxxx. |
6. Xxxxx xxxxxxxxx xxxxxxxxx orgán xxxxxx, xx xxxxxxxx xxxxx xxxxxxx xxxxxx xxxx nebo zvířat xxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxxxx účinků xxxxxxxxxx x xxxxxxxxx biocidních xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx účinné xxxxx, xxx obavy xxxxxxxxxxxx x xxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxx II xxxx 3 xxxxxxx XX nařízení Evropského xxxxxxxxxx x Xxxx (XX) x. 1907/2006 (8) a zahrne xx do xxxxx xxxxxx.
7. X případě xxxxxxx xx xxxxxxxxx hodnocení xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxx zbytečného xxxxxxx x xxxxxxxxxx xxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx odstavce 3:
|
x) |
předloží xxxxx xxxxxxxx xxxxx xx. 37 xxxx. 1 xxxxxxxx (XX) x. 1272/2008, xxxxxxxx xx domnívá, xx xx xxxxxxx jedno x xxxxxxxx xxxxxxxxx x xx. 36 xxxx. 1 xxxxxxxxx xxxxxxxx, xxx xxxx xxxxxxxx xxxxxx x xxxxx 3 xxxxxxx XX xxxxxxxxx nařízení; |
|
b) |
konzultuje s agenturou, xxxxx se xxxxxxx, xx xxxxx x xxxxxxxx xx. 5 xxxx. 1 písm. d) xxxx x) nařízení (XX) x. 528/2012 nebo xxxxxxxx xx. 10 xxxx. 1 xxxx. x) xxxxxxxxx nařízení jsou xxxxxxx, xxx nejsou xxxxxxxx xxxxxx x xxxxxxx XXX nařízení (XX) x. 1907/2006 xxxx x xxxxxxx xxxxxxxx x xx. 59 xxxx. 1 xxxxxxxxx nařízení. |
Xxxxxx 7
Xxxxxxxxxx xxxxxxxx
1. Xxxxx xxxxxx se xxxxxxx, xxxxx platí xxxxxxx x xxxxxx podmínek:
|
a) |
xxxxx hodnotící xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx zprávu podle xx. 6 xxxx. 2 a xxxxxxxx předložil xxxxx xxxx xxxxxxx xxxxxxxxxx xxxxx čl. 6 xxxx. 7; |
|
x) |
xxxxx xxxx xxxxxxxxxx Xxxxxx xxxxxx xxxxxxxxxxx orgánu xxxxx xx. 14 odst. 4 xxxxxxxx (XX) č. 1451/2007, xxx xxxxxxxxx xxxxxx xxxxx xxxxxxxxxxxx Xxxxx xxxxx xxx biocidní xxxxxxxxx xxxxx čl. 15 xxxx. 4 xxxxxxxxx nařízení. |
2. Po xxxxxxx xxxxxx xxxxxxxx xxxxxxxxx a předloží Xxxxxx xxxxxxxxxx o schválení xxxxxxxxx xxxxx a typu xxxxxxxxx xxxx xxxx zařazení xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx X xxxxxxxx (XX) x. 528/2012, xxxxxxxx xxxxxx, x xxxxxxx xx xxxxxx hodnotícího xxxxxxxxxxx xxxxxx.
Xxxxxxxx xxxxxx přípravu xxxxxxxxxx x xxxxx x xxxxxx xxxx, xxxxx xxxx, xx xxxxxxx později:
|
x) |
do xxx xxxxxx xx xxxxxxx xxxxxx; |
|
b) |
xx lhůtě xxxxxxxxx x xxxxxxx XXX. |
Xxxxxxxx xxxxxxxx xxxxxxxxxx Komisi xx 270 dnů od zahájení xxxxxxxx.
Xxxxxx 8
Účinné xxxxx, xxxxx xx mají xxxxxxxx
1. Xxx přípravě svého xxxxxxxxxx xxxxx xx. 7 xxxx. 2 xxxxxxxx prověří, xxx xxxxxx xxxxx xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx v čl. 10 xxxx. 1 xxxxxxxx (XX) x. 528/2012, x xxxx otázku xxxxx xx xxxx xxxxxxxxxx.
2. Xxxx xxxx xxxxxxx xxxxxx 66 x 67 nařízení (EU) x. 528/2012, dříve xxx xxxxxxxx předloží xxx xxxxxxxxxx Xxxxxx, xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxx, xxxxx xx xxxx xxxxxxxx, během xxxxxxxxx 60 xxx; x xxxx době xxxxx xxxxxxxxxx xxxxx strany xxxxxxxxx příslušné xxxxxxxxx xxxxxx xxxxxxxxx x xxxxxxxxxx xxxxxxxxx. Agentura xxxxxxxx xxxxxxxxx náležitě xxxxxxxx x xxxxxxxxx xxxx xxxxxxxx xxxxx xxxxxxxxxx.
3. Xxxxx xx xxxxxx xxxxx xxxxxxxxx x xxxxxxx xxxxx x xxxxxxxx xxxxxxxxxxx x xx. 10 xxxx. 1 xxxxxxxx (XX) x. 528/2012, xxxx xxx xxxxxxxx xx xxxxx, xxxxx se má xxxxxxxx, v nařízení xxxxxxxx x xxxxxxx x xx. 89 xxxx. 1 xxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx 9
Xxxxxxxxxx Komise
Po xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxx xx. 7 odst. 2 Xxxxxx bez xxxxxxxxxx xxxxxxxx připraví návrh xxxxxxxxxx pro xxxxxxx xxxxx xx. 89 odst. 1, xxxx xxxxxxxx xxxxx xx. 28 xxxx. 1 xxxxxxxx (XX) x. 528/2012.
XXXXXXXX 3
ZMĚNY PRVKŮ XXXXXXXX PŘEZKUMU
Článek 10
Připojení xxxx xxxxxxxxx účastníků xx vzájemné xxxxxx
1.&xxxx;&xxxx;&xxxx;Xxxx xxxxxxxxx xx xxxxx xx xxxxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxxxxx x potenciálním xxxxxxxxxx xxxxxxx xxxx sdílet xx předpokladu, že xx xxxxxxxxxxx účastník xxxxx xxxxxxxxx xx xx xxxxxxx údaje xxxxxxxxxx xxxx uvedené xxxxxxxxxx xxxxxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxxx xxx xxxxx xxxxxx článku xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxx účastník xxxxxxxxxxxxxxx rejstříku xxx xxxxxxxx přípravky xxxxxxxxx x článku 71 xxxxxxxx (EU) x. 528/2012 (dále xxx „xxxxxxxx“) x&xxxx;xxxxxxxx xxxx xxxxxxxxx všechna xxxxxxxxx xxxxxxxx x přístupu.
3. Po xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx 2 xxxxxxxx xxxxxxxxxxx xxxxxxxxx v rejstříku xxxxxxxx xx xxxxxxxxxx xxxxxxxxx.
4.&xxxx;&xxxx;&xxxx;Xxxxx xxxxxxx xx&xxxx;xxxxx Xxxx, xxxxx xxxxxxxx xxxx xxxxxxxxx xxxx xx xxxxxxxxx x xxxxxxxxxxx xxxxx xxxxxx xxxxxx, xx xxx účely xxxxxx 95 xxxxxxxx (XX) x.&xxxx;528/2012 xxxxxxxxxx xx xxxxx, která xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx x xxxxxxxx x xxxxxxxxxxx.
Xxxxxx 11
Odstoupení xxxxxxxxx
1. Xx xx xx xx, xx xxxxxxxx xxxxxxxxx x xxxxxx xx xxxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx v programu xxxxxxxx, x xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxxxxxxxxx agenturu xxxx xxxxxxxxx xxxxxxxxx xxxxx prostřednictvím xxxxxxxxx x xxxx xxxxxx xxxxxxxxx; |
|
x) |
xxxxx xxxxxxxxxxx žádost xx xxxxx xxxxxxx x xx. 3 xxxx. 2; |
|
x) |
xxxxx xxxx xxxxxx xxxx xxxxxxxxx xxxxx čl. 4 xxxx. 1, xx. 4 xxxx. 4 xxxx xx. 5 xxxx. 4; |
|
d) |
xxxxx xxxxxxxxxxx xxxxxxxxxx informace xx xxxxxxx xxxxxxxxx x xx. 6 xxxx. 5; |
|
x) |
xxxxx xxxxx xxxxxxxxxx xxxxxxxx hodnotícímu xxxxxxxxxxx xxxxxx xxxx xxxxxxxx. |
2. Xxxxxxxxxx xx xxxxxxxx xx xxxxxxxxx xxxx, xxxxx x němu xxxxxxx xx xxxx, xxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx žadateli zprávu xxxxxxxxxxx xxxxxx xxxxx xx. 6 xxxx. 4 xxxxxx xxxxxxxx.
Xxxxxx 12
Xxxxxxxx xxxxxxxx xxxxxxxxxx
1. Xxxxx xx x xxxxxxx odstoupení informován xxxxxxxxx příslušný orgán, xxx nikoli agentura, xxxxxxxxx ji xxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxx je x xxxxxxx xxxxxxxxxx informována xxxxxxxx, xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx týkající xx xxxxxxxxxx xxxxxxxxx.
3. Xxxxx x xxxxxxxx xxxxxxxx xxxx xxxxxxxxxx všichni účastníci xxxxxxxxxxx tutéž kombinaci xxxxx a typu přípravku x xxxxx xxxx role xxxxxxxxx pro uvedenou xxxxxxxxx xxxxx xxxxxxxx, xxxxxxxxx x tom xxxxxxxx xxxxxxxxxxxxxxx rejstříku Xxxxxx.
Xxxxxx 13
Xxxx xxxxxxxx xxxxxxxxx xxxxx
1. Xxxxx hodnocení xxxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxxx xxxxxxxx se xxxxx, xxx xxxx xxxxxxx x xxxxxxx XX, xxxxxxxxx xxxxxxxxx xxxxx xx konzultaci x xxxxxxxx xxxxxxxxxx xxxxxxx xxxxx xxxxxxxx xxxxx. Xxxxxxxxx xxxxxxxxx xxxxx x xxx informuje xxxxxxxx.
2. Xxxxxxxx v rejstříku aktualizuje xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx.
Xxxxxx 14
Xxxxxxxx role xxxxxxxxx
1. Xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx k xxxxxxxx xxxx účastníka xxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, pokud xxxxxxx xxxxx x xxxxxx xxxxxxx:
|
a) |
xxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxx xxxxxxxxxx xxxxx článku 11 x xxxxxx xxxx xxxxxxxxx xxx xxxxx xxxxxxxxx xxxxxx xxxxxxx xxxxxxxx; |
|
x) |
xx xxxxxxx xxxx definice xxxxx xxxxxx 13; v tomto xxxxxxx xx xxxxx týká xxxxx xx xxxxx, xx xxxxxx xx vztahuje xxxxxxxxx xxxxxxxx x xxxxxxx XX, xxx xxxxxxx nová xxxxxxxx látky. |
2. Xx xxxxxxxx měsíců xxx xxx xxxxxxxxxx xxxxx odstavce 1 xxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx podle článku 17.
3. Xx xxxxxxxx xxxxxx xx xxxx xxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxx xxxxx xxxxxxx xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxxxxxx xx xxxxx 2 přílohy II xxxxx xxxxxx 17.
Xxxxxx 15
Kombinace xxxxx x typu přípravku xxxxxxxxx xxx xxxxxxxx xx xxxxxxxx přezkumu
Xxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxx xx xxxxxxx xxxxxxxxxx nařízení (XX) x. 528/2012 a xx xxxxxx xx xxx, xxxxxxx xx xxxxxxxxx xxxxxx xxxxx, xxx xxxx xxxxxxxxx xxx xxxxxxxx do xxxxxxxx xxxxxxxx xxx xxxxx xxx xxxxxxxxx a xxxx xxxxxxxx do xxxxxxx X uvedeného xxxxxxxx, tuto xxxxx xxxxxxxx nebo se x xx xxxxxx, xx uvedená xxxxx xxxxxxxxx xxx zařazení xx xxxxxxxx xxxxxxxx xxx xxxxxxxxx xxx přípravku xx xxxxxxx některého z těchto xxxxxx:
|
x) |
xxxxx xxxxxxxxx výrobek xx xxx xx xxxxxxxxx xx xxxxxx nebo xxxxxxx doporučení xxxxxx Xxxxxx xxxx příslušným xxxxxxx xxxxxxxxxx x xxxxxxx x xxxxxxx 26 xxxxxxxx 98/8/XX xxxx xxxxxxx 81 xxxxxxxx (XX) x. 528/2012, xxxxx na základě xxxxxxxxxx xxxxxxxxxxxxxx důvodů xxxxx xxxxxxx xxxxxx xx xxxxxxxxxx x xxxxxxxxxxx, že výrobek xxx xxxxx x xxxxxxxxxx směrnice 98/8/XX xxxx xxxxxxxx (XX) č. 528/2012, xxxx xx byl xxxxxxxxx xxx přípravku jedním x xxxxxxxxx, pro xxxxx xxxx xxxxxx xxxxx oznámena, x xxxxx xxxx uvedené xxxxxx či doporučení xxxxxxxx xxxxxxxxxxx x xxxxxxxxxx přijatém xxxxx xx. 3 xxxx. 3 xxxxxxxx (XX) x. 528/2012 xxxx x xxxxxx, závazných xxxxxxxx xxxxxxxxxxxx Xxxxxx; |
|
b) |
xxxxx xxxxxxxxx odchylky xxx xxxxxxxxx a krmiva xxxxxxxxx x xxxxxx 6 xxxxxxxx (XX) č. 1451/2007; |
|
c) |
xxxxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxx (XX) x. 528/2012 x xxxxxxxxx xxxx xxxxxxxxx, xxx xxxx bylo xxxxx směrnice 98/8/ES, x xxxxxxxx xxxxx xxxxxxxxxx xxxxxx xxxx xxxxxxxxx x xxxxxxxx xxxxx xxxxxxxxx xx xxxxxxxx xxxxxxxx xxx xxxxxxx xxx xxxxxxxxx, xxx xxxxxx xxx xxxx. |
Xxxxxx 16
Xxxxxxxxxx x xxxxx na oznámení
1. Prohlášení x xxxxx xxxxxxx látku, xxxxx je způsobilá xxx zařazení xx xxxxxxxx xxxxxxxx xxxxx xxxxxx 15, xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx osoba, xxx xx zájem xxxxxxx xxxxxxxxx xxxxx x xxxx přípravku, xxxxxxx x následujících příjemců:
|
x) |
Komisi xxxxxxxxxx xxxxxxx měsíců xx xxxxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxxxxxxx x xx. 15 xxxx. x); |
|
x) |
xxxxxxxx xxxxxxxxxx 30. října 2015 x xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x); |
|
x) |
Komisi xxxxxxxxxx 30. xxxxx 2015 x xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x). |
2. Xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxx kombinaci látky x xxxx xxxxxxxxx. X xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x) xxxx xxxxxxxxxx xxxxxxxxx opodstatněné odůvodnění, x xxxx xxxxxxx, xx xxxx splněny xxxxxxx xxxxxxxx v xxx uvedené.
3. Pokud xxxx xxxxxxxxxx učiněno x xxxxxxx xxxxxxxx x xx. 15 xxxx. x) nebo x) x Xxxxxx xxxxxxx xx xxxxxxxxxx s členskými xxxxx x závěru, xx xxxxxxxx 6 xxxx xxxxxxxxxx, a případně, xx xxxx xxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxx x xx. 15 písm. a), xxxxxxx o xxx xxxxxxxx.
4. Xxxxx xxxx xxxxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 písm. b) xxxx xxxxx Xxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 3, zveřejní agentura xxxx informaci xxxxxxxxxxxxxx xxxxxxxxxx s uvedením příslušné xxxxxxxxx xxxxx a typu xxxxxxxxx. Xxx účely xxxxxx xxxxxxxx xx xxxxxxxxxx xxxxx xx. 3x xxxx. 3 třetího pododstavce xxxxxxxx (XX) x. 1451/2007 xxxxxxxx xx zveřejnění xxxxx xxxxxx odstavce.
5. Kterákoli xxxxx, xxxxx xx xxxxx oznámit xxxxxxxxx xxxxx x typu xxxxxxxxx, tak xxxx xxxxxx podle článku 17 xx xxxxx xxxxxx xxx xxx zveřejnění xxxxx xxxxxxxx 4.
6. X xxxxxxxxx xxxxxxxxx v čl. 15 písm. x) x x) xx xxxxxxxxx látky x xxxx xxxxxxxxx xxxxxxxx xx xxxxxxxxx xxxxxxxxxx x xxxx xxxxxxxxx x dalšímu xxxxxxxx, pokud xxxx xxxxxxx xxxx xxxxxxxx:
|
x) |
příslušná xxxxxx xxxxx je xxx zařazena xx xxxxxxxx xxxxxxxx; |
|
x) |
xxxxxxxxxxx předložená xxxxxxxxxxx xxxxxxxxx státu pro xxxxxxxxxx účinnou látku xxx xxxxxxxx xxxxxxx xxxxx, xxxxx jsou xxxxxxxx xxx xxxxxxxxx xxxx xxxxxxxxx; |
|
x) |
xxxxxxxx, který xxxxxxxxx dotyčnou dokumentaci, xxxxx, že má xxxxx x xxxxxxx xxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx. |
Xxxxxx 17
Xxxxxx xxxxxxxx
1. Xxxxxxxx xxxxx xx. 14 odst. 2 x 3 nebo xx. 16 xxxx. 5 xx xxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxxxxx xxxx xxx xxxxxxxxxx ve xxxxxxx XXXXXX. Xxxx obsahovat xxxxx uvedené v xxxxxxx X.
3. Xxxxx není x xxxxxxx XX pro xxxxxxxx xxxxxxx xxxxx xxxxxx xxxxxxxxx příslušný xxxxx, xxxxxxxxx xxxxxxxxxxx agenturu x xxxxx xxx vybraného xxxxxxxxxxx orgánu, xxxxx xx jmenován v souladu x xxxxxxx 81 nařízení (XX) x. 528/2012, x xxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx, xx xxxxxxxxx xxxxx xxxxxxxx x xxx, xx xxxxxxxxxxx xxxxxxx.
4. Xx obdržení oznámení x xxx xxxxxxx xxxxxxxx Komisi x xxxxxxxxxxxx informuje x xxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx (XX) x. 564/2013. Xxxxxxxx xxxxxxxxxxx neuhradí xxxxxxxx xx 30 dnů xx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxxx oznámení xxxxxxx x xxxxxxx x xxx oznamovatele x Komisi.
5. Xx xxxxxxxx xxxxxxxx xxxxxxxx xx 30 xxx xxxxx, xxx oznámení xxxxxxxx xxxxxxxxxx uvedeným v xxxxxxxx 2. Pokud xxxxxxxx těmto xxxxxxxxxx xxxxxxxxxx, poskytne xxxxxxxx xxxxxxxxxxxx lhůtu x xxxxx 30 xxx, xxx xxx xxxxxxxx xxxxxxx nebo opravil. Xx xxxxxxxx xxxx 30xxxxx lhůty xxxxxxxx xx 30 xxx xxx xxxxxxxx, že xxxxxxxx xxxxxxxx požadavkům xxxxxxxx 2, nebo xxxxxxxx xxxxxxx, a xxx xxxxxxxxxx xxxxx xxxxxxxxxxxx x Xxxxxx.
6. X xxxxxxx s xxxxxxx 77 xxxxxxxx (EU) x. 528/2012 xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 4 xxxx 5 xxxxx opravný xxxxxxxxxx.
7. Xxxxx xxxxxxxx xxxxxxxx xxxxxxxxxx podle xxxxxxxx 5:
|
a) |
x xxxxxxx, xx bylo xxxxxxxx xxxxxxxxxx xxxxx xx. 14 xxxx. 2 xxxx 3, agentura neprodleně xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxx látky; |
|
x) |
x xxxxxxx, xx xxxxxxxx xxxx xxxxxxxxxx xxxxx xx. 16 xxxx. 5, xxxxxxxx xxxxxxxxxx xxxxxxxxx Xxxxxx, že xxxxxxxxxx xxxx xxxxxxxx. |
Xxxxxx 18
Zařazení xx xxxxxxxx přezkumu
Pokud xx xxxxxxxxx xxxxx a typu xxxxxxxxx považována za xxxxxxxxx x xxxxxxx x xx. 16 xxxx. 6 xxxx xxxxx xxxxxxxx xxxxxxxxx Komisi x xxxxxxxx xxxxxxxxx x souladu x xx. 17 xxxx. 7 xxxx. x), xxxxxx Xxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xx xxxxxxxx xxxxxxxx.
Xxxxxx 19
Xxxxxxxxx x xxxxxxx, xxxxx xxxxxx xxxxxx xxxxxxxxxxx x xxxxx programu přezkumu
Pokud xxxxxx ve lhůtě xxxxxxxxx x xx. 16 xxxx. 5 xxxxxxxx xxxxx xxxxxxxx nebo xxxxx byla oznámení xxxxxxx xx zmíněném xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 4 nebo 5, xxxxxxxx o tom xxxxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxxxx rejstříku x xxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxx.
Xxxxxx 20
Xxxxxxxxxx Komise x látkách, které xxxxxx xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxx
Xxxxxx xxxxxxxx xxxxx xxxxxxxxxx x xxxxxxxxxxx xxxxx čl. 89 odst. 1 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) x. 528/2012 x xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxxxxxxx xxxxxxxxx Xxxxxx x xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xx. 12 xxxx. 3 tohoto xxxxxxxx; |
|
x) |
xxxxx xxxxx osoba nepodala xxxxxxxx xx xxxxxxx xxxxxxxxxxx x xx. 14 xxxx. 2 xxxx 3 tohoto xxxxxxxx xxxx pokud xxxx xxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxx xx. 17 xxxx. 4 xxxx 5; |
|
c) |
xxxxx xxxx xxxxxxxx předloženo ve lhůtě xxxxxxxxx x xx. 14 xxxx. 2 xxxx 3 xxxxxx xxxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxxxx xx. 17 xxxx. 5 tohoto xxxxxxxx, xxx xxxxxxxx xxxxx x xxxxxxxx zahrnuje xxxxx xxxx xxxxxxxxx identity x xxxxxxx XX xxxxxx xxxxxxxx. |
V případě xxxxxxxx x xxxxxx pododstavci xxxx. x) se xxxxx xxxxxxxxxx o xxxxxxxxxxx xxxxxxxx xx xxxxxx látku, xx xxxxxx xx xxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx, xxxxx xxxxxx xxxxxxxx xxxx xxxxxxxx xxxxxxxxxx x schválení.
XXXXXXXX 4
PŘECHODNÁ OPATŘENÍ
Článek 21
Xxxxxxxxx xxxxxxxx xxx xxxxx xxxxxxx v článku 15
1. Členský xxxx může xxxxxxxxxx x&xxxx;xxxxxxxxxxx svého stávajícího xxxxxxx nebo xxxxx xxxxxxxx xx&xxxx;xxx a používání xxxxxxxxxx přípravku, který xxxxxxx xx xxxxxxxxx xxxxxx xxxxx xxxxxxx x xx. 15 xxxx. x) a x), xxxx xxxxx xxxxxxxx nebo x xx xxxxxx. X xxxxxx případech:
|
a) |
nesmí xxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx xx xxxx vstupu tohoto xxxxxxxx v platnost; |
|
b) |
stávající xxxxxx xxxxxxxxxx přípravku xxxxx xxx xxxx xxxxxxxxx xx&xxxx;30 xxxxxx xx xxx xxxxxx xxxxxx xxxxxxxx x&xxxx;xxxxxxxx. |
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx pokračovat x&xxxx;xxxxxxxxxxx xxxxx stávajícího systému xxxx xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, který sestává xx xxxxxxxxx účinné xxxxx xxxxxxx x xx. 15 písm. x), xxxx látku xxxxxxxx xxxx z xx xxxxxx. X xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxx xxxxxxxx xxxxxxxxx nadále xxxxxxx na trh x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx xx xx z xxxx xxxxxxxxx xxxxxxxx, která xxxxxxx xxxxxxx:
|
|
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx dále xxxxxxxxx xx&xxxx;30 měsíců xx xx x xxxx xxxxxxxxx xxxxxxxx, xxxxx xxxxxxx xxxxxxx:
|
3.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx v uplatňování xxxxx xxxxxxxxxxx systému xxxx xxxxx dodávání xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx přípravku, xxxxx xxxxxxx ze xxxxxxxxx xxxxxx xxxxx xxxxxxxxxx agenturou xxxxx xx. 16 odst. 4 pro příslušný xxx xxxxxxx, xxxx xxxxx xxxxxxxx xxxx x ní xxxxxx. X xxxxxx xxxxxxxxx:
|
x) |
xxxxx xxx xxxxxxxx přípravek xxxxxx xxxxxxx na trh x&xxxx;xxxxxxx od dvanácti měsíců xx xxxx, xxx xxxxxxxx xxxxxxxx elektronické xxxxxxxxxx xxxxx článku 19 a |
|
b) |
stávající zásoby xxxxxxxxxx přípravku xxxxx xxx xxxx xxxxxxxxx xx&xxxx;xxxxxxxx xxxxxx po xxxx xxxxxxxxx zveřejnění. |
Xxxxxx 22
Xxxxxxxx xxxxxxx
1. Xxxx xx xxxxxx čl. 55 xxxx. 1 xxxxxxxx (XX) x. 528/2012, xx xxxxxxxx xxxxxx xx xxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxxxxx xxxxxx xxxxx, xxxxx členský stát xxxxxxxx tuto xxxxxxxxx xxxxxxx xxxxx xx xxxxxxxxx x xxxxxx xxxxxxxxx x xx. 5 xxxx. 2 xxxxxx xxxxxxxxxxx xxxx. x) xxxx x) xxxxxxxx (XX) x. 528/2012, xxxxx xxxxxxx xxxx xxxx předložit Xxxxxx xxxxxxxxxxx xxxxxx x xxxxxxxx xx xx. 89 xxxx. 2 xxxxxxx xxxxxxxxxxx uvedeného xxxxxxxx.
2. Xxxxxxxx xxxxxxx stát xxxxxxxx xxxxxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxxxxxxx rejstříku. Xxxxx xxxxxx xxxxxxxx xxxxxxx informace, xxxxxxxx xxxxxxx xxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxxxxx xxxxxx xxxx případně xxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxxxxxxxxx. Xxxxxxx xxxxx xxxx xxxx xxxxx mohou xxxxx xxxxxxxxxx xx xxxxx 60 dnů po xxxxxxxxxx.
4. Xx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxx Komise xxxxxxx xxxxxxxx xx xx. 89 xxxx. 2 xxxxxxx xxxxxxxxxxx xxxxxxxx (EU) x. 528/2012, xxxxx xxxxxx xxxxxx xxxxxxxx přípravky, jež xxxxxxxxx x xxxx xxxxx, obsahují ji xxxx x ní xxxxxxxx, na xxx xxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx je x xxxxx xxxxxxxx xxxxx x xxxxxxx x xxxxxxxxxxxxxx právními xxxxxxxx x x xxxxxxxx podmínek xxxxxxxx 5 x xxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx Komisí.
5. Xxxxxxx xxxx, jemuž je xxxxxxxx xxxxxxxx:
|
a) |
zajistí, že další xxxxxxxxx xxxx omezeno xx xxxxxx případy x xxxxxxx xxxx, kdy xxxx xxxxxx xxxxxxxx xxxxxxxx 1; |
|
x) |
xxxxxx xxxxxx xxxxxxxx xx xxxxxxxx xxxxx, aby xxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxx, xxxxxx xxxx xxxxxxxxx prostředí; |
|
c) |
xxxxxxx, xxx xx xxxxxxx alternativní xxxxxx xxxx xxx xxxx xxxx xxxx xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxx x xxxxxxxxx xxxxxx xxxxx x xxxxxxx xxxxxxx 7 xxxxxxxx (XX) č. 528/2012. |
XXXXXXXX 5
ZÁVĚREČNÁ USTANOVENÍ
Článek 23
Xxxxxxx
Xxxxxxx se xxxxxxxx (XX) x. 1451/2007.
Odkazy xx xxxxxxx xxxxxxxx xx xxxxxxxx xx xxxxxx xx toto xxxxxxxx.
Xxxxxx 24
Xxxxx x xxxxxxxx
Xxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx xxxx xx xxxxxxxxx x Xxxxxxx věstníku Xxxxxxxx unie.
Xxxx xxxxxxxx xx xxxxxxx x xxxxx xxxxxxx x přímo xxxxxxxxxx xx všech xxxxxxxxx státech.
X Bruselu xxx 4. srpna 2014.
Xx Komisi
předseda
José Manuel XXXXXXX
(1) Úř. xxxx. X 167, 27.6.2012, s. 1.
(2)&xxxx;&xxxx;Xxxxxxxx Komise (XX) x. 1451/2007 xx xxx 4. prosince 2007 o xxxxx xxxxx xxxxxxxxxxxx pracovního xxxxxxxx xxxxxxxxx x xx. 16 xxxx. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx 98/8/XX x xxxxxxx xxxxxxxxxx přípravků xx xxx (Úř. xxxx. X 325, 11.12.2007, x. 3).
(3)&xxxx;&xxxx;Xxxxxxxx Evropského parlamentu x Xxxx 98/8/XX xx dne 16. xxxxx 1998 o xxxxxxx xxxxxxxxxx přípravků xx trh (Xx. xxxx. L 123, 24.4.1998, x. 1).
(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxx dvora (xxxxxxx senátu) xx xxx 1. xxxxxx 2012 (xxxxxx o xxxxxxxxxx x xxxxxxxxx xxxxxx: Xxxxxxxxxxx Hamburg – Německo) – Xöxx XxxX proti Xxxxx GmbH (uvádění xxxxxxxxxx xxxxxxxxx xx xxx – xxxxxxxx 98/8/XX – xx. 2 xxxx. 1 xxxx. a) – xxxxx „xxxxxxxx xxxxxxxxx“ – xxxxxxxxx, který xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxx xx xxxx, odpuzuje xxxx xxxxxxxxxxx), C-420/10.
(5)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Xxxxxx (XX) x.&xxxx;88/2014 xx xxx 31. ledna 2014, xxxxxx xx xxxxxxx xxxxxx pro xxxxx xxxxxxx X&xxxx;xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 x&xxxx;xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx x&xxxx;xxxxxx používání (Úř. xxxx. X 32, 1.2.2014, x. 3).
(6)&xxxx;&xxxx;Xxxxxxxx Evropského parlamentu x Rady (XX) x. 1272/2008 xx xxx 16. prosince 2008 x klasifikaci, xxxxxxxxxx x xxxxxx xxxxx x směsí, x xxxxx x xxxxxxx xxxxxxx 67/548/EHS x 1999/45/XX x x xxxxx nařízení (XX) x. 1907/2006 (Xx. xxxx. X&xxxx;353, 31.12.2008, x. 1).
(7) Prováděcí xxxxxxxx Komise (XX) x.&xxxx;564/2013 xx xxx 18.&xxxx;xxxxxx 2013 x&xxxx;xxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx podle xxxxxxxx Evropského parlamentu x&xxxx;Xxxx (XX) x.&xxxx;528/2012 x&xxxx;xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx x&xxxx;xxxxxx xxxxxxxxx (Xx.&xxxx;xxxx.&xxxx;X 167, 19.6.2013, x. 17).
(8)&xxxx;&xxxx;Xxxxxxxx Evropského xxxxxxxxxx x Rady (XX) x. 1907/2006 xx xxx 18. xxxxxxxx 2006 x xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx a xxxxxxxxx chemických xxxxx, x xxxxxxx Xxxxxxxx xxxxxxxx pro chemické xxxxx, x xxxxx xxxxxxxx 1999/45/XX a x xxxxxxx nařízení Xxxx (XXX) x.&xxxx;793/93, xxxxxxxx Xxxxxx (ES) x. 1488/94, směrnice Xxxx 76/769/XXX x xxxxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/XX x 2000/21/XX (Xx. xxxx. X 396, 30.12.2006, x. 1).
XXXXXXX X
Informace požadované xxx xxxxxxxx podle xxxxxx 17
Xxxxxxxx xxxxx xxxxxx 17 xxxxxxxx xxxx informace:
|
1) |
xxxxx, xx xxxxx xx stávající xxxxxxx xxxxxx xx xxxxxx xx. 3 xxxx. 1 xxxx. x) xxxxxxxx (XX) x. 528/2012; |
|
2) |
xxxxx o xxxx/xxxxxx xxxxxxxxx, na xxxxx/x xx xxxxxxxx xxxxxxxx; |
|
3) |
xxxxxxxxx x xxxxx xxxxxxxx, xxxxx xxxx zadány xxx xxxxx xxxxxxx x xxxxxxxxx či xxxxxxxx xx xxxxxxx X xxxxxxxx (XX) x. 528/2012, xxxxx x xxxxxxxxx xxxxx xxxxxx xxxxxxxxx; |
|
4) |
informace xxxxxxx x xxxxxxxx
|
|
5) |
pokud xxxx xxxx xxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 xxxx. x), xxxxx, xx xxxxx xxxx xx xxxx xxxx xxxxxx xxxxx biocidního xxxxxxxxx xxxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxxxxxx x xxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxxxxx xxxx pokynů xxxxxxxxx xx zmíněném xxxxxxx. |
XXXXXXX XX
XXXXXXXXX LÁTKY X XXXX XXXXXXXXX XXXXXXXX XX XXXXXXXX XXXXXXXX XXX 4. XXXXX 2014
XXXX 1
Xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxxxx xx dni 4. xxxxx 2014, x xxxxxxxx xxxxxxxxxx jiných xxxxxxxxxxxxx xxx xxxx, xxxxx xxxx xxxxxxxx uvedeny x xxxxxxxxx 1017 x 1019.
|
Xxxxx xxxxxxx |
Xxxxx xxxxx |
Xxxxxxx stát xxxxxxxxx |
Xxxxx XX |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1 |
formaldehyd |
XX |
200-001-8 |
50-00-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
6 |
5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6- xxxxxx-1,3-xxxxxxxxxxx (xxxxxxxxxxxxxxxx/XXX) |
XX |
200-076-7 |
51-03-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
9 |
xxxxxxxx |
XX |
200-143-0 |
52-51-7 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
|
|
|
|
|
x |
|
29 |
xxxxxxxxxxx |
XX |
200-431-6 |
59-50-7 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
36 |
xxxxxxx |
XX |
200-578-6 |
64-17-5 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37 |
xxxxxxxx xxxxxxxx |
XX |
200-579-1 |
64-18-6 |
|
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
40 |
propan-2-ol |
XX |
200-661-7 |
67-63-0 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43 |
xxxxxxxx salicylová |
XX |
200-712-3 |
69-72-7 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
xxxxxx-1-xx |
XX |
200-746-9 |
71-23-8 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
xxxxxxxxxxx |
N |
200-849-9 |
75-21-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60 |
xxxxxxxx xxxxxxxxx |
XX |
201-069-1 |
77-92-9 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69 |
xxxxxxxxx xxxxxxxx/2-xxxxxxxxxxxxxxx xxxxxxxx |
XX |
201-180-5 |
79-14-1 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70 |
xxxxxxxx xxxxxxxxxxxx |
XX |
201-186-8 |
79-21-0 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
71 |
X-(+)-xxxxxx xxxxxxxx |
XX |
201-196-2 |
79-33-4 |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
79 |
2-xxxxxxxxxxx-8,9-xxxxxxxxx-1,2,6,6x,12,12x-xxxxxxxxxxxxxxxxx[3,4-x]xxxx[2,3-x]xxxxxxx-6-xx (rotenon) |
XX |
201-501-9 |
83-79-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
85 |
xxxxxxxxx |
XX |
201-782-8 |
87-90-1 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
92 |
xxxxxxx-2-xx |
XX |
201-993-5 |
90-43-7 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
113 |
xxxxxxxxxxxxx/3-xxxxxxxxx-2-xxxx (xxxxxxxxxxxxx) |
XX |
203-213-9 |
104-55-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 |
xxxxxxxx |
XX |
203-377-1 |
106-24-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
122 |
xxxxxxx |
XX |
203-474-9 |
107-22-2 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
xxxx-2,4-xxxxxxx xxxxxxxx (kyselina xxxxxxx) |
XX |
203-768-7 |
110-44-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
136 |
xxxxxxxx (glutaraldehyd) |
XX |
203-856-5 |
111-30-8 |
|
x |
x |
x |
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
154 |
xxxxxxxxx |
X |
204-385-8 |
120-32-1 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171 |
2-fenoxyethan-1-ol |
XX |
204-589-7 |
122-99-6 |
x |
x |
|
x |
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
172 |
cetylpyridinium-chlorid/1-hexadecylpyridin-1-ium-chlorid |
XX |
204-593-9 |
123-03-5 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179 |
xxxx uhličitý |
XX |
204-696-9 |
124-38-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
180 |
(natrium-kakodylát) – xxxxxxx-xxxxxxxxxxxxxxx |
PT |
204-708-2 |
124-65-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
185 |
xxxxxxxxxxxxxx, xxxxx xxx (xxxxx sůl xxxxxxxxxxxxxxx – xxxxxxxxx X) – (X-xxxxx-4-xxxxxxxxxxxx-1-xxxxxxxxxx |
ES |
204-854-7 |
127-65-1 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
187 |
xxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
UK |
204-875-1 |
128-03-0 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
188 |
natrium-dimethyldithiokarbamát |
XX |
204-876-7 |
128-04-1 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
195 |
xxxxxxx-xxxxxxx-2-xxxx |
XX |
205-055-6 |
132-27-4 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
198 |
N-[(trichlormethyl)sulfanyl]ftalimid (xxxxxx) |
XX |
205-088-6 |
133-07-3 |
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
206 |
xxxxxx |
XX |
205-286-2 |
137-26-8 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
210 |
xxxxxx-xxxxxxx |
XX |
205-293-0 |
137-42-8 |
|
|
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
235 |
xxxxxx |
XX |
206-354-4 |
330-54-1 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
239 |
xxxxxxxxxxxxx |
XX |
206-992-3 |
420-04-2 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
253 |
xxxxxxxxxx-3,5-xxxxxxxx-1,3,5-xxxxxxxxxx-2-xxxxx (xxxxxxx) |
BE |
208-576-7 |
533-74-4 |
|
|
|
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
279 |
N-[(dichlorfluormethyl)sulfanyl]-N′,N′-dimethyl-N-(4-methylfenyl)sulfonamid (xxxxxxxxxxxx) |
XX |
211-986-9 |
731-27-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
283 |
xxxxxxxxx |
XX |
212-950-5 |
886-50-0 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
288 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X-xxxxx-X′,X′-xxxxxxxxxxxxxxxx (xxxxxxxxxxxxx) |
XX |
214-118-7 |
1085-98-9 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
|
289 |
xxxxxxxxxxxx měďný |
XX |
214-183-1 |
1111-67-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
292 |
[(1,3-xxxxx-1,3,4,5,6,7-xxxxxxxxx-2X-xxxxxxxx-2-xx)xxxxxx]-xxxxx-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxx-xxxxxxxxxxxx) |
XX |
214-619-0 |
1166-46-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
958 |
xxxxxxxx xxxxxxxx/xxxxxxxxxxx xxxxx/xxxxxx xxxxx |
XX |
215-137-3 |
1305-62-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
xxxx xxxxxxxx/xxxxx/xxxxxx xxxxx/xxxxxxxx xxxxx |
XX |
215-138-9 |
1305-78-8 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306 |
xxxx xxxxx |
FR |
215-270-7 |
1317-39-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
315 |
xxxxx-2-xx-xxxxxxx |
XX |
215-661-2 |
1338-23-4 |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
321 |
xxxxxxxxxxx |
XX |
217-129-5 |
1746-81-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330 |
N-(3-aminopropyl)-N-dodecylpropan-1,3-diamin (xxxxxx) |
XX |
219-145-8 |
2372-82-9 |
|
x |
x |
x |
|
x |
|
x |
|
|
x |
x |
x |
|
|
|
|
|
|
336 |
N,N′-dimethyl-2,2′-disulfandiyldibenzamid (XXXXX) |
XX |
219-768-5 |
2527-58-4 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
339 |
1,2-xxxxxxxxxxxxxxx-3(2X)-xx (BIT) |
ES |
220-120-9 |
2634-33-5 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
341 |
2-xxxxxxxxxxxxxxxxxxxxxxxxxx-3(2X)-xx (XXX) |
XX |
220-239-6 |
2682-20-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
346 |
xxxxxxx-xxxxxxxxxxxxxxxxxx xxxxxxxx |
XX |
220-767-7 |
51580-86-0 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
345 |
xxxxxxx-xxxxxxxxxxxxxxxxxx |
XX |
220-767-7 |
2893-78-9 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
348 |
xxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxx-xxxxxx (XXX) |
PL |
221-106-5 |
3006-10-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
triklosan |
XX |
222-182-2 |
3380-34-5 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 |
(xxxxxxxxxxxx)xxxxxxxxxx (reakční xxxxxxxx ethylenglykolu a xxxxxxxxxxxxxxxx (XXXxxx)) |
XX |
222-720-6 |
3586-55-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
365 |
xxxxxxx-2-xxxxx-1-xxxx, xxxxx xxx (xxxxxxxxx xxxxx) |
XX |
223-296-5 |
3811-73-2 |
|
x |
x |
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
368 |
1-(3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
223-805-0 |
4080-31-3 |
|
|
|
|
|
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
377 |
1,3,5-xxxx(2-xxxxxxxxxxxx)xxxxxxxxx-1,3,5-xxxxxxx (XXX) |
PL |
225-208-0 |
4719-04-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
382 |
1,3,4,6-xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxxxxxxxxx[4,5-x]xxxxxxxx-2,5-xxxx (TMAD) |
XX |
226-408-0 |
5395-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
387 |
xxxxxxxxxxxxxxxxx (XXX) |
XX |
227-062-3 |
5625-90-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
392 |
xxxxxxxx-xxxxxxxxxxxx |
XX |
228-652-3 |
6317-18-6 |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
393 |
1,3-xxx(xxxxxxxxxxxxx)-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX) |
XX |
229-222-8 |
6440-58-0 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
397 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
230-525-2 |
7173-51-5 |
x |
x |
x |
x |
|
x |
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
x |
|
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
403 |
měď |
XX |
231-159-6 |
7440-50-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
405 |
oxid xxxxxxxx |
XX |
231-195-2 |
7446-09-5 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
424 |
xxxxxx sodný |
XX |
231-599-9 |
7647-15-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
432 |
xxxxxxxx xxxxx |
IT |
231-668-3 |
7681-52-9 |
x |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
434 |
xxxxxxxxxxxx |
XX |
231-711-6 |
7696-12-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
439 |
xxxxxxx xxxxxx |
XX |
231-765-0 |
7722-84-1 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
444 |
7x-xxxxxxxxxxxx-1X,3X,5X-xxxxxxx[3,4-x]xxxxxx (XXXX) |
XX |
231-810-4 |
7747-35-5 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
450 |
dusičnan xxxxxxxx |
SE |
231-853-9 |
7761-88-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
xxxxxxxxxxxxx xxxxx |
XX |
231-892-1 |
7775-27-1 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 |
xxxxxxxx xxxxxxxx |
XX |
231-908-7 |
7778-54-3 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
457 |
xxxxx |
XX |
231-959-5 |
7782-50-5 |
|
x |
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
458 |
síran xxxxxx |
XX |
231-984-1 |
7783-20-2 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
473 |
xxxxxxxxxx x xxxxxxxxxxx |
XX |
232-319-8 |
8003-34-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
491 |
oxid xxxxxxxxxx |
XX |
233-162-8 |
10049-04-4 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
494 |
2,2-dibrom-2-kyanacetamid (XXXXX) |
XX |
233-539-7 |
10222-01-2 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
501 |
xxxxxxxxxxx |
XX |
234-232-0 |
10605-21-7 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
515 |
xxxxxx xxxxxx |
XX |
235-183-8 |
12124-97-9 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
522 |
zink-1-oxo-1λ5-pyridin-2-thiolát |
SE |
236-671-3 |
13463-41-7 |
|
x |
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
x |
|
|
524 |
xxxxxxxxxxxxxxx-xxxxxxxxxxxxxxxx |
XX |
237-030-0 |
13590-97-1 |
|
|
|
|
|
x |
|
|
|
|
x |
|
|
|
|
|
|
|
|
526 |
xxxxxx-xxxxxxx-2-xxxx |
XX |
237-243-9 |
13707-65-8 |
|
|
|
|
|
x |
|
|
x |
x |
|
|
x |
|
|
|
|
|
|
529 |
brommonochlorid |
NL |
237-601-4 |
13863-41-7 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
531 |
(xxxxxxxxx)xxxxxxxx |
XX |
238-588-8 |
14548-60-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
534 |
xxx(1-xxxxxxxxxxxxxx-2(1X)-xxxxxxxx-X,X)xxxxxxx komplex (xxxxxxxxx mědi) |
XX |
238-984-0 |
14915-37-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
541 |
natrium-4-chlor-3-methylfenolát |
XX |
239-825-8 |
15733-22-9 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
|
550 |
5,5′-xxx(4-xxxxxxxxxx)-1,1′-(xxxxx-1,6-xxxx)xxx(xxxxxxxx)-xxx(x-xxxxxxxx) (XXXX) |
XX |
242-354-0 |
18472-51-0 |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
XX |
243-468-3 |
20018-09-1 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
|
|
|
559 |
[(xxxxxxxxxxxx-2-xx)xxxxxxxx]xxxxxx-xxxxxxxxxx (XXXXX) |
X |
244-445-0 |
21564-17-0 |
|
|
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
562 |
[2-xxxxxx-4-xxx-3-(xxxx-2-xx-1-xx)xxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
XX |
245-387-9 |
23031-36-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
563 |
kalium-(E,E)-hexa-2,4-dienoát (sorbát xxxxxxxx) |
XX |
246-376-1 |
24634-61-5 |
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
566 |
α, α′,α′′-xxxxxxxxxxxxxxxxxx-1,3,5-xxxxxxx-1,3,5-xxxxxxxxxx (XXX) |
XX |
246-764-0 |
25254-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
571 |
2-xxxxxxxxxxxxxxxxxxxxxxxxx-3-xx (OIT) |
UK |
247-761-7 |
26530-20-1 |
|
|
|
|
|
x |
x |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
577 |
dimethyl(oktadecyl)[3-(trimethoxysilyl)propyl]amonium-chlorid |
XX |
248-595-8 |
27668-52-6 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
578 |
N2-terc-butyl-N4-cyklopropyl-6-(methylsulfanyl)-1,3,5-triazin-2,4-diamin (xxxxxxxx) |
XX |
248-872-3 |
28159-98-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
588 |
xxxxxxxxx-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (BCDMH/bromchlordimethylhydantoin) |
XX |
251-171-5 |
32718-18-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
|
590 |
3-(4-isopropylfenyl)-1,1-dimethylmočovina/isoproturon |
XX |
251-835-4 |
34123-59-6 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
|
597 |
1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]xxxxxxxx (imazalil) |
XX |
252-615-0 |
35554-44-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
599 |
S-[(6-chlor-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl]-O,O-dimethyl-fosforothioát (xxxxxxxxxxx) |
XX |
252-626-0 |
35575-96-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
600 |
2-xxxx-2-(xxxxxxxxxx)xxxxxxxxxxxxxx (XXXXX) |
XX |
252-681-0 |
35691-65-7 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
961 |
oxid vápenato-hořečnatý/dolomitické xxxxx |
XX |
253-425-0 |
37247-91-9 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
962 |
xxxxxxxx vápenato-hořečnatý/hydratované xxxxxxxxxxx xxxxx |
XX |
254-454-1 |
39445-23-3 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
606 |
[(3-xxxxxxxxxxx)xxxxxxxxxx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (cyfenothrin) |
XX |
254-484-5 |
39515-40-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
608 |
xxxxxxxx(xxxxxxxxxx)[3-(xxxxxxxxxxxxxxx)xxxxxx]xxxxxxx-xxxxxxx |
PL |
255-451-8 |
41591-87-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
609 |
xxx- a xxxxx-x-xxxxxxx-3,8-xxxx (xxxx) (citriodiol) |
UK |
255-953-7 |
42822-86-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
614 |
(RS)-α-kyano-3-fenoxybenzyl-(1RS)-cis,trans-3-(2,2-dichlorvinyl)-2,2-dimethylcyklopropanekarboxylát (xxxxxxxxxxxx) |
XX |
257-842-9 |
52315-07-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxx) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
618 |
[1-xxxxxxx-2-xxxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxx) |
XX |
259-154-4 |
54406-48-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
619 |
3-xxxxxxx-2-xx-1-xx-X-xxxxxxxxxxxxx (XXXX) |
XX |
259-627-5 |
55406-53-6 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
620 |
xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxx (2:1) (XXXX) |
XX |
259-709-0 |
55566-30-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
|
628 |
(±)-1-{[2-(2,4-xxxxxxxxxxxx)-4-xxxxxx- 1,3-xxxxxxxx-2-xx]xxxxxx}-1X-1,2,4-xxxxxxx (propikonazol) |
XX |
262-104-4 |
60207-90-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
635 |
alkyltrimethylammoniumchlorid xxxxxxxxxx xxxxx (ATMAC/TMAC) |
XX |
263-038-9 |
61789-18-2 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
648 |
4,5-xxxxxxx-2-xxxxxxxxxxxxxxx-3(2X)-xx (4,5-xxxxxxx- 2-xxxxx-2X-xxxxxxxxxx-3-xx (XXXXX)) |
X |
264-843-8 |
64359-81-5 |
|
|
|
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
649 |
1-(2-chlorbenzyl)-3-[(trifluormethoxy)fenyl]močovina (triflumuron) |
XX |
264-980-3 |
64628-44-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
656 |
xxx(5-xxxxxxxxxxxxxxxx-3-xx)xxxxxx (xxxxxxxxxx/XXX) |
XX |
266-235-8 |
66204-44-2 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
657 |
6-(xxxxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxxx) |
XX |
266-257-8 |
66215-27-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
666 |
[(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (cyfluthrin) |
XX |
269-855-7 |
68359-37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
667 |
xxxxx(X12-18)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-18)) |
IT |
269-919-4 |
68391-01-5 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
671 |
xxxxx(X12-16)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (ADBAC/BKC (X12-X16)) |
XX |
270-325-2 |
68424-85-1 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
673 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (XXXX) (X8-10) |
IT |
270-331-5 |
68424-95-3 |
x |
x |
x |
x |
|
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
690 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxxx xxxx 1,1-xxxxx-1λ-1,2-xxxxxxxxxxxxxxx-3(2X)-xxx (XXXXX) |
XX |
273-545-7 |
68989-01-5 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691 |
xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx |
XX |
274-357-8 |
70161-44-3 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
XX |
274-687-2 |
70592-80-2 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
693 |
xxx(xxxxxxxxxxx)-xxx(xxxxx) xxxxxxxxxxxxx |
XX |
274-778-7 |
70693-62-8 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
701 |
xxxxxxxxx-xxxxxxxxxxxxxxxx xxxxxxxxxx (XXXX) |
PL |
279-013-0 |
84665-66-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1015 |
xxxxxxx, Xxxxxxxxxxx indica, xxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
724 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-X14)) |
XX |
287-089-1 |
85409-22-9 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
725 |
alkyl(C12-C14)ethylbenzylammoniumchlorid (XXXXXX (X12-X14)) |
XX |
287-090-7 |
85409-23-0 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
731 |
xxxxxxxxx stračkolistá, Chrysanthemum xxxxxxxxxxxxxxxx, xxxxxxx |
XX |
289-699-3 |
89997-63-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
744 |
levandule xxxxxx, Xxxxxxxxx xxxxxxx, xxxxxxx/xxxxxxxxxxx xxxx |
XX |
294-470-6 |
91722-69-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
776 |
1-[3,5-xxxxxxx-4-(1,1,2,2-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxxxx)xxxxxxxx (hexaflumuron) |
PT |
401-400-1 |
86479-06-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
779 |
xxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx a X-xxxxx(X12-X14)xxxxxx-1,2-xxxxxxx (xxxxxxxxxxxxx) |
XX |
403-950-8 |
164907-72-6 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785 |
6-xxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx (XXX) |
XX |
410-850-8 |
128275-31-0 |
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
791 |
2-xxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx (XXXX) |
XX |
420-590-7 |
4299-07-4 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
|
792 |
xxxxxxx xxxxxxxxxxxxxxxxxxx (XXXX) |
XX |
420-970-2 |
92047-76-2 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
811 |
xxxxxxxxxxxxxxxxxxx xxxxxxxx-xxxxx-xxxxxxxxxxx |
XX |
422-570-3 |
265647-11-8 |
x |
x |
|
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
794 |
xxx-xxxxx-2,2-(2-xxxxxxxxxxxx)xxxxxxxxx-1-xxxxxxxxxx (ikaridin) |
DK |
423-210-8 |
119515-38-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
797 |
1-((Z)-3-chlorallyl)-3,5,7-triaza-1-azoniaadamantanchlorid (xxx-XXXX) |
XX |
426-020-3 |
51229-78-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
|
800 |
{[2,5-xxxxx-3-(xxxx-2-xx-1-xx)xxxxxxxxxxxx-1-xx]xxxxxx}-2,2-xxxxxxxx-3- (2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx- 1-xxxxxxxxxx (xxxx stereoisomerů) (xxxxxxxxxxx) |
XX |
428-790-6 |
72963-72-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
790 |
5-xxxxx-2-(4-xxxxxxxxxxx)xxxxx (XXXX) |
XX |
429-290-0 |
3380-30-1 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
807 |
(X)-1-[(2-xxxxxxxxxxxx-5-xx)xxxxxx]-3-xxxxxx-2-xxxxxxxxxxxxx (xxxxxxxxxxxxx) |
XX |
433-460-1 |
210880-92-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
952 |
Bacillus sphaericus 2362, kmen XXXX-1743 |
XX |
mikroorganismus |
143447-72-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
955 |
Xxxxxxxx xxxxxxxxxxxxx xxxxx. israelensis, xxxx SA3A |
XX |
xxxxxxxxxxxxxxx |
xxxx relevantní |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
957 |
Xxxxxxxx xxxxxxxx |
XX |
xxxxxxxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928 |
5-chlor-2-methylisothiazol-3(2H)-on (Xxxxxx 247-500-7) x 2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 220-239-6), xxxx (3:1) (xxxx XXXX/XXX) |
XX |
xxxx |
55965-84-9 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
|
939 |
xxxxxxx xxxxx (xxxxxxxx reakcí xxxxxxxx xxxxxxx x xxxxxxxxx sodného xx xxxx) |
XX |
xxxx |
xxxx xxxxxxxxxx |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
813 |
peroxyoktanová xxxxxxxx |
XX |
xxxx xxxxxxxxxx |
33734-57-5 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1014 |
xxxxxxxx xxxxxx |
XX |
není relevantní |
není xxxxxxxxxx |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
XX |
není xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
931 |
xxxxxxxxxxxxxxxxxxxxxxx, X-X12-14(xx xxxxx xxxxxx), xxxxxxxx xxxxxx x xxxxxxxxxxxx xxxxxxxxx (Xxxxxxxx 20) |
XX |
xxxx xxxxxxxxxx |
139734-65-9 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152 |
produkty reakce 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxx x xxxxxxx (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
459 |
xxxxxxx xxxx xxxxx titaničitého x xxxxxxxx xxxxxxxxxx |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
777 |
reakční xxxxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxxx (XXXXX) |
XX |
xxxx x xxxxxxxxx |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
810 |
fosforečnanové xxxx x xxxxxxx xxxxxxx |
XX |
xxxx x xxxxxxxxx |
308069-39-8 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
824 |
stříbrno-zinečnatý zeolit |
XX |
xxxx x xxxxxxxxx |
130328-20-0 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1013 |
xxxxxxxx-xxxxxxx xxxxxx |
XX |
xxxx k dispozici |
130328-19-7 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1017 |
xxxxxxx xxxxxxxxxxx na xxxxx xxxxxxxxxx (xxxx xxxxxxxxxxxx xx xxxxx xxxxxxxxxx agregátu x xxxxxxxxxx xxxxxxxxx xx xxxxxxxxxx) |
XX |
xxxx k dispozici |
xxxx x xxxxxxxxx |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
1019 |
xxxx xxxxxxxxx (xxxx xxxxxxxxxxxx xxxxxxx xxxxxxxx x xxxxxxxxxx) |
XX |
xxxx k dispozici |
68909-20-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
831 |
xxxxxxxxx |
FR |
xxxxxxxxx na xxxxxxx xxxxxxx |
61790-53-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
854 |
(XX)-3-xxxx-2-xxxxx-4-xxxxxxxxxxxx-2-xxxx-(1X,3X;1X,3X)-2,2-xxxxxxx-3-(2-xxxxxxxxx-1-xxxx)-xxxxxxxxxxxxxxxxxxxxx (xxxx 4 xxxxxxx 1X xxxxx, 1X: 1X xxxxx, 1X: 1X xxx, 1X: 1X xxx, 1X 4:4:1:1) (x-xxxxxxxxx) |
XX |
xxxxxxxxx na ochranu xxxxxxx |
231937-89-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
855 |
(XX)-3-xxxxx-2-xxxxxx-4-xxxxxxxxxxxx-2-xx-1-xx-(1X,3X)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (směs 2 xxxxxxxxxxxxx) (xxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx rostlin |
260359-57-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
848 |
X-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X′-xxxx-X-xxxxxxxxxxxxxxxxxxx (xxxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
160430-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
835 |
xxxxxxxxxxxx/(X)-(3-xxxxxxxxxxx)xxxxxxxxxx-(X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx ochranu xxxxxxx |
66230-04-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
836 |
[(3-xxxxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (α-cypermethrin) |
XX |
přípravek xx xxxxxxx xxxxxxx |
67375-30-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
843 |
4-xxxx-2-(4-xxxxxxxxxx)-1-(xxxxxxxxxxxx)-5-(xxxxxxxxxxxxxx)xxxxxx-3-xxxxxxxxxxx (xxxxxxxxxxxx) |
PT |
xxxxxxxxx xx ochranu rostlin |
122453-73-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
859 |
xxxxxxx X-xxxxxxxxxxxxxxxxx(XXXXXX 204-697-4) s (xxxxxxxxxxx)xxxxxxxx (EINECS 203-439-8)/xxxxxxxxx xxxxxxxxx xxxxxxx amonný (XX Xxxxxxx) |
XX |
xxxxxxx |
25988-97-0 |
|
x |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
863 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx) (XXXX) |
FR |
polymer |
27083-27-8/32289-58-0 |
x |
x |
x |
x |
x |
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
868 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx-xxxxxxxxxxxx) |
XX |
polymer |
91403-50-8 |
x |
x |
x |
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
869 |
α-[2-(xxxxxxxxxxxxxxxxxxx)xxxxx]-ω-[xxxxxxxxxxx(xxxxxxxxxx)-xxxxxxxxx] (Xxxxxx 26) |
XX |
xxxxxxx |
94667-33-1 |
|
x |
|
x |
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
872 |
X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx-xxxxx/ α, α ′-(xxxxxxxxxxxxx)xxx[ω-xxxxxxxxx(xxxxxxxxxx)]-xxx xx (xxxxxxxxxxx betain) |
XX |
polymer |
214710-34-6 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
XXXX 2
Xxxxxxxxx účinné látky x xxxx přípravku xxxxxxxxxxxxx xx dni 4. xxxxx 2014
Xxxx xxxx xxxx xxxxxxx obsahuje
|
— |
xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxx v tabulce níže, xxxxxx případných nanoforem, |
|
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxxxxxxx v tabulce v části 1, xxxxx xxxx, xxxxx xxxx xxxxxxx v tabulce, x |
|
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxx přípravku xxxxxxxxxxx xx 4. srpna 2014, x xxxxxxxx těch, xxxxx xxxx xxxxxxxx xxxxxxxxx. |
Xxxxxxxxx xxxxx x xxxx xxxxxxxxx x nanomateriály zařazené xx xxxx části xxxxx předmětem xxxxxxxxxx x neschválení xxxxx xxxxxx 20, xxxxxxxx xxxxx osoba nepodá xxxxxxxx xx xxxxxxxx xxxxxx xx xxxxxx tohoto xxxxxxxx x xxxxxxxx podle xx. 14 odst. 3 nebo xxxxx xx takové xxxxxxxx xxxxxxxxx podle xx. 17 xxxx. 4 xxxx 5.
|
Xxxxx xxxxxxx |
Název látky |
Členský xxxx xxxxxxxxx |
Xxxxx XX |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
|
1021 |
1,3-xxxxxxx-5,5-xxxxxxxxxxxxxxxxx (xxxx definovaný xxxxx xxxxxxx 152) |
XX |
204-258-7 |
118-52-5 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
166 |
xxxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
204-526-3 |
122-18-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
167 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
204-527-9 |
122-19-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213 |
benzyl(dodecyl)dimethylamonium-chlorid (xxx xxxxxxx 948) |
|
205-351-5 |
139-07-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 |
benzyl(dimethyl)tetradecylamonium-chlorid (xxx xxxxxxx 948) |
|
205-352-0 |
139-08-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxx (viz xxxxxxx 949) |
|
219-234-1 |
2390-68-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384 |
xxxxxxxx(xxxxxxx)xxxxxxx-xxxxxxx (xxx položka 949) |
|
226-901-0 |
5538-94-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxx (xxx xxxxxxx 948) |
|
230-698-4 |
7281-04-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
418 |
xxxx xxxxxxxxx xxxxxxx |
XX |
231-545-4 |
7631-86-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
449 |
xxxxx xxxxxxx |
XX |
231-847-6 |
7758-98-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016 |
xxxxxxx stříbrný |
XX |
232-033-3 |
7783-90-6 |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
UK |
243-468-3 |
20018-09-1 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
587 |
decyl(dimethyl)oktylamonium-chlorid (xxx xxxxxxx 949) |
|
251-035-5 |
32426-11-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
601 |
benzyldimethyl(oktadec-9-en-1-yl)amonium-chlorid (viz xxxxxxx 948) |
|
253-363-4 |
37139-99-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
615 |
3-fenoxybenzyl(1RS,3RS;1RS,3SR)-3-(2,2-dichlorvinyl)-2,2-dimethylcyklopropankarboxylát (permethrin) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
637 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx (xxxxx xxxxxxx od xxxxxxxx xxxxxxx kokosového xxxxx) (xxx položka 948) |
|
263-080-8 |
61789-71-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx odvozen xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxx xxxxxxx 949) |
|
263-087-6 |
61789-77-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx od hydrogenovaných xxxxxxxx xxxxxxx loje) (xxx xxxxxxx 949) |
|
263-090-2 |
61789-80-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
647 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
264-151-6 |
63449-41-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668 |
xxxxxxx(X6-X12)xxxxxxxxxxxxxxx-xxxxxxxx (xxx xxxxxxx 949) |
|
269-925-7 |
68391-06-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
670 |
xxxxx(X8-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
270-324-7 |
68424-84-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
689 |
xxxxx(X10-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
273-544-1 |
68989-00-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
XX |
274-687-2 |
70592-80-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
697 |
dialkyl(C8-C18)dimetylamonium-chloridy (xxx položka 949) |
|
277-453-8 |
73398-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
dihydrogen-bis(monoperoxyftalato)magnesát xxxxxxxxxx |
XX |
279-013-0 |
14915-85-4 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
xxxxxxx xxxxxxx xxxx xxx x jader xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxxxxxxxx xxxxx x xxxx xxxxxxxxxx organickými xxxxxxxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
741 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx (xxx položka 948) |
|
293-522-5 |
91080-29-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020 |
1,3-xxxxxxx-5-xxxxx-5-xxxxxxxxxxxxxxxxxx-2,4-xxxx (nově definovaný xxxxx položky 777) |
XX |
401-570-7 |
89415-87-2 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
778 |
1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-3-[(1X-1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxx-3-xx (xxxxxxxxxxx) |
XX |
403-640-2 |
107534-96-3 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
805 |
xxxxxxx produkt dimethyl-adipátu, xxxxxxxx-xxxxxxxxx a xxxxxxxx-xxxxxxxxx x xxxxxxxxx xxxxxx (xxxxxxxx) |
XX |
432-790-1 |
xxxx xxxxxxxxxx |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
923 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxx/xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
směs |
8001-54-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
(dialkyl)dimethylamonium-chloridy, -bromidy xxxx -xxxxxx-xxxxxxx) (xxxxxx (X6-X18) xxxxxxxx x xxxxxxxxxx, odvozené od xxxxxxxx xxxxxxx xxxx, xxxxxxxxxx xxxxx x xxxxxxxx oleje) (XXXX) |
XX |
xxxx xxxxx xxxxxxxxx v xxxxxxx XXXXXX |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
950 |
alkyltrimethylamonium-chloridy, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (xxxxxx (X8-X18) xxxxxxxx x xxxxxxxxxx, xxxxxxxx xx xxxxxxxx xxxxxxx xxxx, xxxxxxxxxx oleje x xxxxxxxx xxxxx) (XXXX) |
XX |
xxxx xxxxx uvedených x seznamu XXXXXX |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
948 |
xxxxxx(xxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx nebo -xxxxxxxxx) (xxxxxx (C8-C22) xxxxxxxx x xxxxxxxxxx, xxxxxxxx xx xxxxxxxx xxxxxxx xxxx, xxxxxxxxxx xxxxx x xxxxxxxx oleje) (XXX) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx XXXXXX |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
IE |
xxxx xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
1001 |
xxxxx(X12-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx xxx xxxxx xxxxxxxxx xxx xxxxxxx 671) |
XX |
xxxx relevantní |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
x |
|
1002 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx(xxxx xxx xxxxx xxxxxxxxx xxx xxxxxxx 667) |
XX |
xxxx xxxxxxxxxx |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1003 |
xxxxx(X12-X18)(xxxxxxxxxxx)xxxxxxxxxxxxxxx- chloridy (xxxx než látka xxxxxxxxx xxx xxxxxxx 725) |
XX |
xxxx relevantní |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1005 |
alkyl(C12-C14)benzyl(dimethyl)amonium-chloridy (xxxx xxx látka xxxxxxxxx xxx xxxxxxx 724) |
XX |
xxxx relevantní |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
|
1006 |
xxxxxxxxxxxxxx xxxx xxxxxxxxxx stříbro, xxxxx, hliník x xxx |
XX |
xxxx xxxxxxxxxx |
398477-47-9 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
1009 |
dialkyl(C8-C10)dimetylamonium-chloridy (xxxx xxx xxxxx xxxxxxxxx xxx položku 673) |
XX |
není xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
x |
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
|
1011 |
xxxxx(xxxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx oleje) (xxxx xxx xxxxx xxxxxxxxx xxx xxxxxxx 635) |
XX |
xxxx relevantní |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
1012 |
xxxxxxxxxxxxxxxxx xxxxx, stříbrný a xxxxxxxxx xxxxxxx/xxxxxxxx-xxxxxxxxx xxxxxx |
XX |
xxxx xxxxxxxxxx |
130328-20-0 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
598 |
(±)-1-(β-xxxxxxxx-2,4-xxxxxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxx xxxxxxxxx) |
DE |
přípravek xx xxxxxxx rostlin |
73790-28-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XXXXXXX XXX
Xxxxx
|
Xxxx xxxxxxxxx |
Xxxxx xxx xxxxxxxxxx xxxxxxxxx zprávy xxxxx xx. 6 xxxx. 3 xxxx. x) |
Xxxxx xxx xxxxxxxx xxxxxxxx stanoviska podle xx. 7 odst. 2 písm. b) |
|
8, 14, 16, 18, 19 x 21 |
31.12.2015 |
31.3.2016 |
|
3, 4 x 5 |
31.12.2016 |
31.3.2017 |
|
1 a 2 |
31.12.2018 |
31.3.2019 |
|
6 x 13 |
31.12.2019 |
31.3.2020 |
|
7, 9 a 10 |
31.12.2020 |
31.3.2021 |
|
11, 12, 15, 17, 20 x 22 |
31.12.2022 |
31.9.2023 |